BACKGROUND AND PURPOSE: Clinical use of cinacalcet in hyperparathyroidism is complicated by its tendency to induce hypocalcaemia, arising partly from activation of calcium-sensing receptors (CaS receptors) in the thyroid and stimulation of calcitonin release. CaS receptor allosteric modulators that selectively bias signalling towards pathways that mediate desired effects [e.g. parathyroid hormone (PTH) suppression] rather than those mediating undesirable effects (e.g. elevated serum calcitonin), may offer better therapies. EXPERIMENTAL APPROACH: We characterized the ligand-biased profile of novel calcimimetics in HEK293 cells stably expressing human CaS receptors, by monitoring intracellular calcium (Ca(2+) i ) mobilization, inositol phosphate (IP)1 accumulation, ERK1/2 phosphorylation (pERK1/2) and receptor expression. KEY RESULTS: Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca(2+) i mobilization and IP1 accumulation. S,R-calcimimetic B was biased only towards IP1 accumulation. R,R-calcimimetic B and AC-265347 were biased towards IP1 accumulation and pERK1/2. Nor-calcimimetic B was unbiased. In contrast to phenylalkylamines and calcimimetic B analogues, AC-265347 did not promote trafficking of a loss-of-expression, naturally occurring, CaS receptor mutation (G(670) E). CONCLUSIONS AND IMPLICATIONS: The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards pERK1/2 and IP1 accumulation may explain their suppression of PTH levels in vivo at concentrations that have no effect on serum calcitonin levels. The demonstration that AC-265347 promotes CaS receptor receptor signalling, but not trafficking reveals a novel profile of ligand-biased modulation at CaS receptors The identification of allosteric modulators that bias CaS receptor signalling towards distinct intracellular pathways provides an opportunity to develop desirable biased signalling profiles in vivo for mediating selective physiological responses.
BACKGROUND AND PURPOSE: Clinical use of cinacalcet in hyperparathyroidism is complicated by its tendency to induce hypocalcaemia, arising partly from activation of calcium-sensing receptors (CaS receptors) in the thyroid and stimulation of calcitonin release. CaS receptor allosteric modulators that selectively bias signalling towards pathways that mediate desired effects [e.g. parathyroid hormone (PTH) suppression] rather than those mediating undesirable effects (e.g. elevated serum calcitonin), may offer better therapies. EXPERIMENTAL APPROACH: We characterized the ligand-biased profile of novel calcimimetics in HEK293 cells stably expressing human CaS receptors, by monitoring intracellular calcium (Ca(2+) i ) mobilization, inositol phosphate (IP)1 accumulation, ERK1/2 phosphorylation (pERK1/2) and receptor expression. KEY RESULTS:Phenylalkylamine calcimimetics were biased towards allosteric modulation of Ca(2+) i mobilization and IP1 accumulation. S,R-calcimimetic B was biased only towards IP1 accumulation. R,R-calcimimetic B and AC-265347 were biased towards IP1 accumulation and pERK1/2. Nor-calcimimetic B was unbiased. In contrast to phenylalkylamines and calcimimetic B analogues, AC-265347 did not promote trafficking of a loss-of-expression, naturally occurring, CaS receptor mutation (G(670) E). CONCLUSIONS AND IMPLICATIONS: The ability of R,R-calcimimetic B and AC-265347 to bias signalling towards pERK1/2 and IP1 accumulation may explain their suppression of PTH levels in vivo at concentrations that have no effect on serum calcitonin levels. The demonstration that AC-265347 promotes CaS receptor receptor signalling, but not trafficking reveals a novel profile of ligand-biased modulation at CaS receptors The identification of allosteric modulators that bias CaS receptor signalling towards distinct intracellular pathways provides an opportunity to develop desirable biased signalling profiles in vivo for mediating selective physiological responses.
Authors: Edward F Nemeth; William H Heaton; Michael Miller; John Fox; Manuel F Balandrin; Bradford C Van Wagenen; Mathew Colloton; William Karbon; Jon Scherrer; Edward Shatzen; Gilbert Rishton; Sheila Scully; Meiying Qi; Robert Harris; David Lacey; David Martin Journal: J Pharmacol Exp Ther Date: 2003-10-30 Impact factor: 4.030
Authors: Albane Kessler; Hélène Faure; Christophe Petrel; Martial Ruat; Philippe Dauban; Robert H Dodd Journal: Bioorg Med Chem Lett Date: 2004-06-21 Impact factor: 2.823
Authors: Katie Leach; Adriel Wen; Anna E Cook; Patrick M Sexton; Arthur D Conigrave; Arthur Christopoulos Journal: Endocrinology Date: 2013-01-31 Impact factor: 4.736
Authors: O Kifor; F D Moore; P Wang; M Goldstein; P Vassilev; I Kifor; S C Hebert; E M Brown Journal: J Clin Endocrinol Metab Date: 1996-04 Impact factor: 5.958
Authors: Craig W Lindsley; Kyle A Emmitte; Corey R Hopkins; Thomas M Bridges; Karen J Gregory; Colleen M Niswender; P Jeffrey Conn Journal: Chem Rev Date: 2016-02-16 Impact factor: 60.622
Authors: Katie Leach; Fadil M Hannan; Tracy M Josephs; Andrew N Keller; Thor C Møller; Donald T Ward; Enikö Kallay; Rebecca S Mason; Rajesh V Thakker; Daniela Riccardi; Arthur D Conigrave; Hans Bräuner-Osborne Journal: Pharmacol Rev Date: 2020-07 Impact factor: 25.468
Authors: Tracy M Josephs; Andrew N Keller; Elham Khajehali; Aaron DeBono; Christopher J Langmead; Arthur D Conigrave; Ben Capuano; Irina Kufareva; Karen J Gregory; Katie Leach Journal: Br J Pharmacol Date: 2020-02-12 Impact factor: 8.739
Authors: Katie Leach; Karen J Gregory; Irina Kufareva; Elham Khajehali; Anna E Cook; Ruben Abagyan; Arthur D Conigrave; Patrick M Sexton; Arthur Christopoulos Journal: Cell Res Date: 2016-03-22 Impact factor: 25.617
Authors: Andrew N Keller; Irina Kufareva; Tracy M Josephs; Jiayin Diao; Vyvyan T Mai; Arthur D Conigrave; Arthur Christopoulos; Karen J Gregory; Katie Leach Journal: Mol Pharmacol Date: 2018-04-10 Impact factor: 4.436